Accessibility Log In Help Join The Motley Fool

Max Macaluso

TMFMassimo

Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.

Recent Articles by Max Macaluso

May 23, 2016 by Max Macaluso and Kristine Harjes

Drawing Biopharma Concepts With A Crayon

Peter Lynch once said, “Never invest in any idea you can’t illustrate with a crayon.” Does that hold true in the highly scientific world of biopharma?

Jun 20, 2014 by Max Macaluso and Joel South

Better Stock Today Challenge: InvenSense vs. Seadrill

In the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.

Jun 18, 2014 by Max Macaluso and Joel South

Better Stock Today Challenge: InvenSense vs. DistributionNow

In the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.

Jun 17, 2014 by Max Macaluso and Mark Reeth

Better Stock Today Challenge: InvenSense vs. SodaStream

In the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.

Jun 17, 2014 by Max Macaluso and David Hanson

Better Stock Today Challenge: Apple vs. Annaly Capital

In the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.

Jun 15, 2014 by Max Macaluso and Dave Williamson

Better Stock Today: InvenSense vs. Johnson & Johnson

In the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.

Jun 15, 2014 by Max Macaluso and Joel South

Better Stock Today: Vanguard Natural Resources vs. Apple

In the spirit of World Cup competition, we’re holding our own tournament in search of the Better Stock Today.

Jun 9, 2014 by Max Macaluso and Eric Bleeker

This Internet of Things Company is Changing Medicine as We Know It

A look at smart-pill pioneer Proteus Digital Health.

Jun 5, 2014 by Max Macaluso and Eric Bleeker

The Biggest Threat to Facebook's $19 Billion WhatsApp Buy

Will smaller, more intimate communication networks like WhatsApp start pulling people away from sprawling ones like Facebook?

Jun 4, 2014 by Max Macaluso and Eric Bleeker

Will Your Car Have No Steering Wheel in 5 Years? Google Makes Its Self-Driving-Car Move

Will Google be able to get its driverless car, or at least the tech behind it, into the marketplace? Or will companies not want to play ball with the Internet giant?

Jun 4, 2014 by Max Macaluso and Eric Bleeker

Why Is Intel Partnering With a Company You've Probably Never Heard Of?

Tech giant Intel has partnered with the relatively unknown Rockchip in an effort to get its chips into inexpensive smartphones and tablets in emerging markets.

Jun 2, 2014 by Max Macaluso and Eric Bleeker

Will Google's Nest Disrupt the Smart Home Industry?

Google Inc.'s Nest thermostat and ADT Corp.'s home security systems are but two of the names filling out the already crowded connected-home market.

May 31, 2014 by Max Macaluso and Eric Bleeker

What's the Future of the Connected TV?

A lot of companies are developing new ways to deliver content to your TV, but will the television watching experience really change in the next few years?

May 30, 2014 by Max Macaluso and Eric Bleeker

AT&T Inc. Dips Its Toes in the Connected Home

AT&T Inc. is trying to connect consumers' homes with its Digital Life program, but will that in any way affect the company's bottom line?

May 28, 2014 by Max Macaluso

Understanding Multiple Sclerosis: An Interview With Novartis' Dr. Gordon Francis

Understanding multiple sclerosis and Novartis' drug Gilenya.

May 20, 2014 by Max Macaluso

An Interview With Harry Kirsch, CFO of Novartis

Novartis CFO Harry Kirsch discusses Novartis' culture and its recent deals with GlaxoSmithKline and Eli Lilly.

Apr 30, 2014 by Max Macaluso and Michael Douglass

CannaVEST Corp.: What Investors Need to Watch

What investors need to watch at CannaVEST

Apr 23, 2014 by Max Macaluso and Matt Koppenheffer

What's Behind the Biotech Crash?

What's the real story behind the rise and fall of the biotech bubble?

Apr 23, 2014 by Max Macaluso and Michael Douglass

Allergan, Inc.: Another Billion-Dollar Buyout Target

Valeant might continue its acquisition streak with the hefty purchase of Allergan.

Apr 10, 2014 by Max Macaluso and Brian Orelli, PhD

Biotech Banter: FDA Delay, Clinical Trial News, and Tweet of the Week

The latest from The Motley Fool's biotech show "Biotech Banter."

HOW THE MOTLEY FOOL CAN HELP YOU

Motley Fool Returns

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns

462%

S&P 500 Returns

125%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2023.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Join Stock Advisor

Cumulative Growth of a $10,000 Investment in Stock Advisor

Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.

Chart Showing the Cumulative Growth of a $10,000 Investment in Stock Advisor

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services